Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15943
Sealed predictions
- EXOC8 in dopamine neurons, braak-0.17 (p 0.668) → -0.05 (p 0.893)receipt 15950
Swarm cases
receipt 15950: EXOC8 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.597, n 18), 95% CI -0.57 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.544, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.544, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.597, n 18). fragile.
- cell type
- strongest in OPCs: -0.62 (p 0.0057, n 18) vs -0.13 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EXOC8 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up EXOC8 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.55 p 0.051 (needs p < 1.4e-4)
Receipts
loading the receipts